Search:
Sunday, Sep-27 2020 10:22 WIB
  • AGRI 1,137.610 23.110 (2.074%)
  • BASIC-IND 706.280 14.200 (2.052%)
  • BISNIS-27 437.930 11.390 (2.670%)
  • COMPOSITE 4,945.790 103.030 (2.128%)
  • CONSUMER 1,841.020 34.940 (1.935%)
  • DBX 931.260 7.760 (0.840%)
  • FINANCE 1,072.260 31.540 (3.031%)
  • I-GRADE 131.320 3.450 (2.698%)
  • IDX30 415.490 11.170 (2.763%)
  • IDX80 108.560 2.910 (2.754%)
  • IDXBUMN20 273.680 10.370 (3.938%)
  • IDXG30 115.600 2.360 (2.084%)
  • IDXHIDIV20 371.560 9.730 (2.689%)
  • IDXQ30 121.640 3.180 (2.684%)
  • IDXSMC-COM 210.240 3.310 (1.600%)
  • IDXSMC-LIQ 235.870 5.970 (2.597%)
  • IDXV30 102.790 3.010 (3.017%)
  • INFOBANK15 787.380 27.060 (3.559%)
  • INFRASTRUC 803.560 4.620 (0.578%)
  • Investor33 363.770 10.190 (2.882%)
  • ISSI 144.700 2.460 (1.729%)
  • JII 523.850 9.500 (1.847%)
  • JII70 177.780 3.740 (2.149%)
  • KOMPAS100 971.120 25.960 (2.747%)
  • LQ45 760.320 20.320 (2.746%)
  • MANUFACTUR 1,181.750 26.720 (2.313%)
  • MBX 1,369.120 31.050 (2.321%)
  • MINING 1,330.110 20.960 (1.601%)
  • MISC-IND 871.510 36.940 (4.426%)
  • MNC36 271.590 7.180 (2.715%)
  • PEFINDO25 259.810 8.180 (3.251%)
  • PROPERTY 342.330 3.910 (1.155%)
  • SMinfra18 233.530 4.870 (2.130%)
  • SRI-KEHATI 306.750 8.930 (2.998%)
  • TOTAL_MARKET 4,945.790 103.030 (2.128%)
  • TRADE 623.470 4.560 (0.737%)
  • © 2010 IMQ - LKBN ANTARA
  • AALI 9,975 225 (2.31%)
  • ABBA 50 0 (0.00%)
  • ABMM 855 -5 (-0.58%)
  • ACES 1,570 130 (9.03%)
  • ACST 184 0 (0.00%)
  • ADES 1,140 25 (2.24%)
  • ADHI 500 10 (2.04%)
  • ADMF 7,250 150 (2.11%)
  • ADMG 116 -1 (-0.85%)
  • ADRO 1,140 10 (0.88%)
  • AGAR 500 0 (0.00%)
  • AGII 486 18 (3.85%)
  • AGRO 322 34 (11.81%)
  • AGRS 184 7 (3.95%)
  • AHAP 51 -1 (-1.92%)
  • AIMS 135 -10 (-6.90%)
  • AISA 218 4 (1.87%)
  • AKPI 284 -14 (-4.70%)
  • AKRA 2,610 100 (3.98%)
  • AKSI 330 -24 (-6.78%)
  • ALDO 394 22 (5.91%)
  • ALKA 214 -16 (-6.96%)
  • ALMI 182 0 (0.00%)
  • ALTO 304 12 (4.11%)
  • AMAG 189 -3 (-1.56%) © 2010 IMQ - LKBN ANTARA
  • AMAN 272 0 (0.00%)
  • AMAR 308 18 (6.21%)
  • AMFG 2,400 -50 (-2.04%)
  • AMIN 240 -2 (-0.83%)
  • AMOR 2,040 0 (0.00%)
  • AMRT 675 15 (2.27%)
  • ANDI 50 0 (0.00%)
  • ANJT 525 -5 (-0.94%)
  • ANTM 730 10 (1.39%)
  • APEX 136 8 (6.25%)
  • APIC 810 5 (0.62%)
  • APII 152 3 (2.01%)
  • APLI 105 3 (2.94%)
  • APLN 97 3 (3.19%)
  • ARGO 1,900 -100 (-5.00%)
  • ARII 424 -12 (-2.75%)
  • ARKA 96 -2 (-2.04%)
  • ARNA 448 0 (0.00%)
  • ARTA 290 -20 (-6.45%)
  • ARTO 2,870 50 (1.77%)
  • ASBI 320 26 (8.84%)
  • ASGR 725 15 (2.11%)
  • ASII 4,860 260 (5.65%)
  • ASJT 112 0 (0.00%)
  • ASPI 124 1 (0.81%) © 2010 IMQ - LKBN ANTARA
  • ASPI-W 15 2 (15.38%)
  • ASRI 114 1 (0.88%)
  • ASSA 484 8 (1.68%)
  • ATIC 560 -40 (-6.67%)
  • AUTO 820 0 (0.00%)
  • AYLS-W 4 0 (0.00%)
  • BABP 50 0 (0.00%)
  • BABP-W3 24 -15 (-38.46%)
  • BABP-W4 8 0 (0.00%)
  • BACA 398 0 (0.00%)
  • BAJA 53 0 (0.00%)
  • BAPI 50 0 (0.00%)
  • BAPI-W 2 -1 (-33.33%)
  • BATA 625 5 (0.81%)
  • BBCA 28,050 825 (3.03%)
  • BBHI 139 0 (0.00%)
  • BBKP 222 10 (4.72%)
  • BBLD 350 14 (4.17%)
  • BBMD 1,485 0 (0.00%)
  • BBNI 4,600 270 (6.24%)
  • BBRI 3,160 130 (4.29%)
  • BBSI 620 10 (1.64%)
  • BBSS 129 -6 (-4.44%)
  • BBSS-W 7 -1 (-12.50%)
  • BBTN 1,235 90 (7.86%) © 2010 IMQ - LKBN ANTARA
  • BBYB 268 0 (0.00%)
  • BCAP 119 0 (0.00%)
  • BCIP 50 0 (0.00%)
  • BDMN 2,220 110 (5.21%)
  • BEEF 145 1 (0.69%)
  • BEEF-W 10 0 (0.00%)
  • BEKS 50 0 (0.00%)
  • BELL 147 1 (0.68%)
  • BESS 222 4 (1.83%)
  • BESS-W 68 8 (13.33%)
  • BEST 171 -2 (-1.16%)
  • BFIN 346 2 (0.58%)
  • BGTG 50 0 (0.00%)
  • BHAT 490 2 (0.41%)
  • BHIT 50 0 (0.00%)
  • BIKA 139 -7 (-4.79%)
  • BINA 805 -15 (-1.83%)
  • BIPI 50 0 (0.00%)
  • BIPI-W 8 0 (0.00%)
  • BIPP 56 1 (1.82%)
  • BIRD 870 20 (2.35%)
  • BISI 885 5 (0.57%)
  • BJBR 885 20 (2.31%)
  • BJTM 515 10 (1.98%)
  • BKSL 50 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • BKSW 71 0 (0.00%)
  • BLUE 565 5 (0.89%)
  • BMAS 266 -10 (-3.62%)
  • BMRI 5,350 275 (5.42%)
  • BMSR 53 1 (1.92%)
  • BMTR 214 4 (1.90%)
  • BNBA 332 0 (0.00%)
  • BNGA 720 15 (2.13%)
  • BNII 206 7 (3.52%)
  • BNLI 1,215 -30 (-2.41%)
  • BOGA 1,380 5 (0.36%)
  • BOLA 167 -1 (-0.60%)
  • BOSS 123 31 (33.70%)
  • BPFI 1,150 -25 (-2.13%)
  • BPTR 81 1 (1.25%)
  • BRIS 770 45 (6.21%)
  • BRMS 57 2 (3.64%)
  • BRNA 980 20 (2.08%)
  • BRPT 675 35 (5.47%)
  • BSDE 755 30 (4.14%)
  • BSIM 470 -8 (-1.67%)
  • BSSR 1,385 -15 (-1.07%)
  • BTEK 50 0 (0.00%)
  • BTON 180 -5 (-2.70%)
  • BTPN 2,100 10 (0.48%) © 2010 IMQ - LKBN ANTARA
  • BTPS 3,090 50 (1.64%)
  • BUDI 94 1 (1.08%)
  • BUKK 730 0 (0.00%)
  • BULL 292 12 (4.29%)
  • BULL-W2 93 8 (9.41%)
  • BUMI 50 0 (0.00%)
  • BUVA 52 -1 (-1.89%)
  • BVIC 66 1 (1.54%)
  • BWPT 93 6 (6.90%)
  • CAKK-W 2 -1 (-33.33%)
  • CAMP 260 2 (0.78%)
  • CANI 118 -3 (-2.48%)
  • CARE 362 -6 (-1.63%)
  • CARS 50 0 (0.00%)
  • CASA 386 0 (0.00%)
  • CASH 615 25 (4.24%)
  • CASH-W 61 8 (15.09%)
  • CASS 200 0 (0.00%)
  • CBMF 348 4 (1.16%)
  • CCSI 248 4 (1.64%)
  • CEKA 1,715 0 (0.00%)
  • CENT 138 -5 (-3.50%)
  • CFIN 186 -1 (-0.53%)
  • CINT 238 0 (0.00%)
  • CITY 96 -4 (-4.00%) © 2010 IMQ - LKBN ANTARA
  • CITY-W 15 1 (7.14%)
  • CLEO 442 0 (0.00%)
  • CLPI 640 0 (0.00%)
  • CMNP 1,110 10 (0.91%)
  • CNTX 244 0 (0.00%)
  • COCO 910 10 (1.11%)
  • CPIN 6,075 175 (2.97%)
  • CPRI 50 0 (0.00%)
  • CSAP 304 -8 (-2.56%)
  • CSIS 50 0 (0.00%)
  • CSMI 246 12 (5.13%)
  • CSRA 314 8 (2.61%)
  • CTRA 645 20 (3.20%)
  • CTTH 51 1 (2.00%)
  • DADA 52 1 (1.96%)
  • DADA-W 4 -1 (-20.00%)
  • DART 234 -4 (-1.68%)
  • DAYA 575 -15 (-2.54%)
  • DEAL 187 27 (16.88%)
  • DFAM 360 -10 (-2.70%)
  • DILD 162 7 (4.52%)
  • DIVA 2,060 75 (3.78%)
  • DKFT 102 2 (2.00%)
  • DLTA 3,940 80 (2.07%)
  • DMAS 214 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • DMMX 167 4 (2.45%)
  • DMND 895 5 (0.56%)
  • DNAR 214 -14 (-6.14%)
  • DNET 3,320 20 (0.61%)
  • DOID 222 4 (1.83%)
  • DPNS 226 -12 (-5.04%)
  • DPUM 68 -5 (-6.85%)
  • DSFI 58 1 (1.75%)
  • DSNG 472 26 (5.83%)
  • DSSA 16,475 1,525 (10.20%)
  • DUCK 238 0 (0.00%)
  • DUTI 3,410 0 (0.00%)
  • DVLA 2,450 0 (0.00%)
  • DWGL 195 -4 (-2.01%)
  • DWGL-W 34 4 (13.33%)
  • DYAN 50 0 (0.00%)
  • EAST 54 3 (5.88%)
  • EAST-W 5 -1 (-16.67%)
  • EKAD 1,220 20 (1.67%)
  • ELSA 200 6 (3.09%)
  • EMTK 6,825 -500 (-6.83%)
  • ENRG 55 4 (7.84%)
  • ENVY 50 -1 (-1.96%)
  • ENZO 76 -5 (-6.17%)
  • ENZO-W 11 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • EPAC 408 32 (8.51%)
  • EPMT 1,830 -5 (-0.27%)
  • ERAA 1,515 -5 (-0.33%)
  • ESIP 145 -7 (-4.61%)
  • ESIP-W 11 -1 (-8.33%)
  • ESSA 136 1 (0.74%)
  • ESTA 97 1 (1.04%)
  • ESTI 50 0 (0.00%)
  • EXCL 1,965 35 (1.81%)
  • FAST 930 -5 (-0.53%)
  • FASW 6,700 -100 (-1.47%)
  • FILM 190 5 (2.70%)
  • FIRE 270 70 (35.00%)
  • FITT 55 -1 (-1.79%)
  • FITT-W 17 0 (0.00%)
  • FOOD 115 0 (0.00%)
  • FPNI 109 0 (0.00%)
  • FREN 77 6 (8.45%)
  • FREN-W 37 6 (19.35%)
  • FUJI 106 0 (0.00%)
  • GDST 57 -4 (-6.56%)
  • GGRM 40,700 525 (1.31%)
  • GGRP 308 -22 (-6.67%)
  • GHON 1,780 185 (11.60%)
  • GIAA 220 10 (4.76%) © 2010 IMQ - LKBN ANTARA
  • GJTL 416 8 (1.96%)
  • GLOB 110 -8 (-6.78%)
  • GLVA 302 -10 (-3.21%)
  • GMFI 83 15 (22.06%)
  • GOLD 206 0 (0.00%)
  • GOOD 1,250 5 (0.40%)
  • GPRA 50 0 (0.00%)
  • GSMF 99 -2 (-1.98%)
  • GWSA 88 -3 (-3.30%)
  • GZCO 50 0 (0.00%)
  • HDIT 404 20 (5.21%)
  • HEAL 3,300 -60 (-1.79%)
  • HELI 192 21 (12.28%)
  • HELI-W 6 1 (20.00%)
  • HERO 805 0 (0.00%)
  • HEXA 3,610 30 (0.84%)
  • HITS 500 0 (0.00%)
  • HKMU 71 2 (2.90%)
  • HMSP 1,455 40 (2.83%)
  • HOKI 745 25 (3.47%)
  • HOMI 685 0 (0.00%)
  • HOTL 50 0 (0.00%)
  • HRME 50 0 (0.00%)
  • HRTA 194 -2 (-1.02%)
  • HRUM 1,620 -5 (-0.31%) © 2010 IMQ - LKBN ANTARA
  • IATA 50 0 (0.00%)
  • IBFN-W 6 2 (50.00%)
  • ICBP 10,050 -50 (-0.50%)
  • IDPR 174 28 (19.18%)
  • IFII 122 -1 (-0.81%)
  • IFSH 370 0 (0.00%)
  • IGAR 320 2 (0.63%)
  • IKAI 50 0 (0.00%)
  • IKAN 304 16 (5.56%)
  • IKBI 220 2 (0.92%)
  • IMAS 650 55 (9.24%)
  • IMJS 232 6 (2.65%)
  • IMPC 1,255 10 (0.80%)
  • INAF 2,910 580 (24.89%)
  • INAI 332 2 (0.61%)
  • INCI 600 0 (0.00%)
  • INCO 3,620 110 (3.13%)
  • INDF 7,125 0 (0.00%)
  • INDO 109 6 (5.83%)
  • INDO-W 25 2 (8.70%)
  • INDR 2,170 10 (0.46%)
  • INDS 1,900 -10 (-0.52%)
  • INDY 925 20 (2.21%)
  • INKP 9,100 25 (0.28%)
  • INOV 170 -4 (-2.30%) © 2010 IMQ - LKBN ANTARA
  • INPC 50 0 (0.00%)
  • INPC-W 3 0 (0.00%)
  • INPP 695 -5 (-0.71%)
  • INPS 1,450 170 (13.28%)
  • INRU 800 20 (2.56%)
  • INTA 248 8 (3.33%)
  • INTD 187 34 (22.22%)
  • INTP 10,900 300 (2.83%)
  • IPCC 372 0 (0.00%)
  • IPCM 232 2 (0.87%)
  • IPOL 84 -2 (-2.33%)
  • IPTV 280 -2 (-0.71%)
  • IPTV-W 26 1 (4.00%)
  • IRRA 790 35 (4.64%)
  • ISAT 1,945 15 (0.78%)
  • ISSP 116 2 (1.75%)
  • ITIC 625 -10 (-1.57%)
  • ITMA 480 6 (1.27%)
  • ITMA-W 60 -14 (-18.92%)
  • ITMG 8,175 125 (1.55%)
  • JAST 74 5 (7.25%)
  • JAWA 51 -1 (-1.92%)
  • JAYA 74 3 (4.23%)
  • JAYA-W 10 2 (25.00%)
  • JIHD 440 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • JMAS 185 -13 (-6.57%)
  • JPFA 1,115 40 (3.72%)
  • JRPT 416 8 (1.96%)
  • JSMR 3,430 180 (5.54%)
  • JTPE 900 0 (0.00%)
  • KAEF 2,880 570 (24.68%)
  • KARW 57 1 (1.79%)
  • KAYU 50 0 (0.00%)
  • KBAG 96 19 (24.68%)
  • KBAG-W 6 0 (0.00%)
  • KBLI 320 32 (11.11%)
  • KBLM 192 1 (0.52%)
  • KBLV 270 -12 (-4.26%)
  • KDSI 735 0 (0.00%)
  • KEEN 298 8 (2.76%)
  • KEJU 1,255 -25 (-1.95%)
  • KICI 248 38 (18.10%)
  • KIJA 166 7 (4.40%)
  • KINO 2,850 50 (1.79%)
  • KIOS 172 -10 (-5.49%)
  • KIOS-W 26 1 (4.00%)
  • KKGI 200 0 (0.00%)
  • KLBF 1,580 65 (4.29%)
  • KMDS 540 15 (2.86%)
  • KMTR 300 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • KOBX 99 -5 (-4.81%)
  • KOPI 468 10 (2.18%)
  • KOTA 600 5 (0.84%)
  • KOTA-W 388 -2 (-0.51%)
  • KPAL 50 0 (0.00%)
  • KPAS 50 0 (0.00%)
  • KPAS-W 10 1 (11.11%)
  • KPIG 102 0 (0.00%)
  • KRAS 302 16 (5.59%)
  • KREN 100 1 (1.01%)
  • LAND 185 -5 (-2.63%)
  • LEAD 50 0 (0.00%)
  • LIFE 4,910 -50 (-1.01%)
  • LINK 1,825 10 (0.55%)
  • LION 240 -6 (-2.44%)
  • LMAS 50 0 (0.00%)
  • LMPI 84 -4 (-4.55%)
  • LMSH 260 0 (0.00%)
  • LPCK 770 10 (1.32%)
  • LPGI 3,280 10 (0.31%)
  • LPIN 214 0 (0.00%)
  • LPKR 122 3 (2.52%)
  • LPLI 86 0 (0.00%)
  • LPPF 1,045 5 (0.48%)
  • LPPS 79 -5 (-5.95%) © 2010 IMQ - LKBN ANTARA
  • LRNA 149 0 (0.00%)
  • LSIP 925 40 (4.52%)
  • LTLS 428 8 (1.90%)
  • LUCK 177 -3 (-1.67%)
  • MAIN 515 15 (3.00%)
  • MAMI 50 0 (0.00%)
  • MAMI-W 5 1 (25.00%)
  • MAPA 2,010 0 (0.00%)
  • MAPI 580 20 (3.57%)
  • MARI 50 0 (0.00%)
  • MARK 780 20 (2.63%)
  • MASA 560 -10 (-1.75%)
  • MBAP 2,030 30 (1.50%)
  • MBSS 372 12 (3.33%)
  • MBTO 81 -4 (-4.71%)
  • MCAS 1,975 140 (7.63%)
  • MCOR 110 6 (5.77%)
  • MDKA 1,555 25 (1.63%)
  • MDKI 154 7 (4.76%)
  • MDLN 51 1 (2.00%)
  • MDRN 50 0 (0.00%)
  • MEDC 372 12 (3.33%)
  • MEDC-W 23 2 (9.52%)
  • MERK 2,900 90 (3.20%)
  • META 105 3 (2.94%) © 2010 IMQ - LKBN ANTARA
  • MFMI 515 -10 (-1.90%)
  • MGRO 795 0 (0.00%)
  • MICE 290 0 (0.00%)
  • MIDI 1,310 10 (0.77%)
  • MIKA 2,410 40 (1.69%)
  • MKPI 20,000 1,500 (8.11%)
  • MLBI 8,350 100 (1.21%)
  • MLIA 364 4 (1.11%)
  • MLPL 50 0 (0.00%)
  • MLPT 575 10 (1.77%)
  • MMLP 280 0 (0.00%)
  • MNCN 715 10 (1.42%)
  • MOLI 905 -45 (-4.74%)
  • MPMX 388 8 (2.11%)
  • MPOW 57 0 (0.00%)
  • MPPA 99 0 (0.00%)
  • MPRO 810 -10 (-1.22%)
  • MRAT 135 2 (1.50%)
  • MSIN 282 12 (4.44%)
  • MSKY 900 -30 (-3.23%)
  • MTDL 1,605 20 (1.26%)
  • MTLA 400 -2 (-0.50%)
  • MTPS 380 -28 (-6.86%)
  • MTSM 200 0 (0.00%)
  • MTWI 50 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • MYOH 1,110 -30 (-2.63%)
  • MYOR 2,420 50 (2.11%)
  • NATO 446 6 (1.36%)
  • NELY 140 3 (2.19%)
  • NFCX 1,770 -40 (-2.21%)
  • NIKL 735 145 (24.58%)
  • NIRO 145 2 (1.40%)
  • NISP 720 -5 (-0.69%)
  • NOBU 850 0 (0.00%)
  • NRCA 292 4 (1.39%)
  • NZIA 131 -9 (-6.43%)
  • OASA 370 30 (8.82%)
  • OKAS 76 0 (0.00%)
  • OPMS 156 6 (4.00%)
  • PADI 50 0 (0.00%)
  • PALM 254 -4 (-1.55%)
  • PAMG 88 -4 (-4.35%)
  • PANI 105 16 (17.98%)
  • PANR 83 2 (2.47%)
  • PANS 765 15 (2.00%)
  • PBID 885 15 (1.72%)
  • PBRX 216 6 (2.86%)
  • PBSA 440 -30 (-6.38%)
  • PCAR 422 74 (21.26%)
  • PDES 222 -14 (-5.93%) © 2010 IMQ - LKBN ANTARA
  • PEGE 112 1 (0.90%)
  • PEHA 1,460 290 (24.79%)
  • PGAS 995 35 (3.65%)
  • PGJO 38 0 (0.00%)
  • PGUN 300 0 (0.00%)
  • PICO 152 2 (1.33%)
  • PJAA 470 2 (0.43%)
  • PKPK 50 0 (0.00%)
  • PLAN 189 9 (5.00%)
  • PLAN-W 19 4 (26.67%)
  • PLIN 2,550 -190 (-6.93%)
  • PMJS 125 0 (0.00%)
  • PNBN 745 15 (2.05%)
  • PNBS 50 0 (0.00%)
  • PNGO 545 -30 (-5.22%)
  • PNIN 690 -5 (-0.72%)
  • PNLF 180 5 (2.86%)
  • POLA 50 -1 (-1.96%)
  • POLI 1,010 -5 (-0.49%)
  • POLY 50 0 (0.00%)
  • PORT 470 -20 (-4.08%)
  • POSA-W 2 0 (0.00%)
  • POWR 580 10 (1.75%)
  • PPGL 264 12 (4.76%)
  • PPGL-W 16 -1 (-5.88%) © 2010 IMQ - LKBN ANTARA
  • PPRE 136 3 (2.26%)
  • PPRO 50 0 (0.00%)
  • PRAS 116 0 (0.00%)
  • PRDA 2,970 30 (1.02%)
  • PRIM 246 18 (7.89%)
  • PRIM-W 4 0 (0.00%)
  • PSAB 191 7 (3.80%)
  • PSDN 103 0 (0.00%)
  • PSGO 115 0 (0.00%)
  • PSSI 162 2 (1.25%)
  • PTBA 1,990 40 (2.05%)
  • PTIS 154 0 (0.00%)
  • PTPP 840 30 (3.70%)
  • PTPW 1,205 65 (5.70%)
  • PTRO 1,640 120 (7.89%)
  • PTSN 200 2 (1.01%)
  • PTSP 4,750 0 (0.00%)
  • PURA 131 -7 (-5.07%)
  • PURA-W 19 0 (0.00%)
  • PURI 396 50 (14.45%)
  • PWON 346 2 (0.58%)
  • PYFA 955 190 (24.84%)
  • PZZA 590 5 (0.85%)
  • R-LQ45X 799 24 (3.10%)
  • RAJA 113 6 (5.61%) © 2010 IMQ - LKBN ANTARA
  • RALS 565 10 (1.80%)
  • RANC 400 4 (1.01%)
  • RBMS 50 0 (0.00%)
  • RDTX 6,225 -75 (-1.19%)
  • REAL 50 0 (0.00%)
  • REAL-W 2 -1 (-33.33%)
  • RICY 92 2 (2.22%)
  • RIGS 228 8 (3.64%)
  • RISE 436 -4 (-0.91%)
  • RMBA 430 0 (0.00%)
  • ROCK 1,410 -105 (-6.93%)
  • RODA 50 0 (0.00%)
  • RONY 96 -7 (-6.80%)
  • ROTI 1,215 10 (0.83%)
  • RUIS 230 -6 (-2.54%)
  • SAFE 172 3 (1.78%)
  • SAME 120 -2 (-1.64%)
  • SAMF 386 4 (1.05%)
  • SBAT 268 -20 (-6.94%)
  • SBAT-W 15 -9 (-37.50%)
  • SCCO 10,000 -200 (-1.96%)
  • SCMA 1,160 15 (1.31%)
  • SCNP 244 4 (1.67%)
  • SDPC 109 10 (10.10%)
  • SDRA 800 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • SFAN 955 10 (1.06%)
  • SGER 372 4 (1.09%)
  • SGER-W 82 7 (9.33%)
  • SGRO 1,460 25 (1.74%)
  • SHIP 550 10 (1.85%)
  • SIDO 755 25 (3.42%)
  • SILO 4,510 60 (1.35%)
  • SIMP 306 18 (6.25%)
  • SINI 448 20 (4.67%)
  • SINI-W 298 103 (52.82%)
  • SIPD 1,200 80 (7.14%)
  • SKBM 284 -12 (-4.05%)
  • SKRN 690 35 (5.34%)
  • SLIS 4,930 20 (0.41%)
  • SMAR 2,820 -80 (-2.76%)
  • SMBR 500 90 (21.95%)
  • SMCB 985 20 (2.07%)
  • SMDM 96 3 (3.23%)
  • SMDR 272 -4 (-1.45%)
  • SMGR 8,800 0 (0.00%)
  • SMKL 181 3 (1.69%)
  • SMMT 81 0 (0.00%)
  • SMRA 535 15 (2.88%)
  • SMSM 1,150 -10 (-0.86%)
  • SOCI 118 2 (1.72%) © 2010 IMQ - LKBN ANTARA
  • SOFA 73 6 (8.96%)
  • SOFA-W 5 1 (25.00%)
  • SOHO 10,975 -800 (-6.79%)
  • SOSS 400 0 (0.00%)
  • SOTS 216 0 (0.00%)
  • SOTS-W 34 0 (0.00%)
  • SPMA 286 12 (4.38%)
  • SPTO 442 -14 (-3.07%)
  • SQMI 166 -2 (-1.19%)
  • SRAJ 128 2 (1.59%)
  • SRIL 196 7 (3.70%)
  • SRSN 53 1 (1.92%)
  • SRTG 3,100 50 (1.64%)
  • SSIA 430 8 (1.90%)
  • SSMS 795 5 (0.63%)
  • SSTM 406 40 (10.93%)
  • STAR 125 -2 (-1.57%)
  • STTP 7,000 0 (0.00%)
  • SWAT 94 0 (0.00%)
  • TALF 274 10 (3.79%)
  • TAMA 157 0 (0.00%)
  • TAMA-W 6 0 (0.00%)
  • TAMU 50 0 (0.00%)
  • TAXI 50 0 (0.00%)
  • TBIG 1,350 25 (1.89%) © 2010 IMQ - LKBN ANTARA
  • TBLA 740 20 (2.78%)
  • TBMS 725 10 (1.40%)
  • TCID 6,450 -25 (-0.39%)
  • TCPI 5,175 185 (3.71%)
  • TDPM 143 4 (2.88%)
  • TECH 180 25 (16.13%)
  • TFAS 170 1 (0.59%)
  • TFCO 476 -34 (-6.67%)
  • TGRA 122 22 (22.00%)
  • TIFA 486 6 (1.25%)
  • TINS 675 -5 (-0.74%)
  • TIRA 258 0 (0.00%)
  • TKIM 6,200 100 (1.64%)
  • TLKM 2,690 -40 (-1.47%)
  • TMAS 109 -4 (-3.54%)
  • TMPO 114 0 (0.00%)
  • TNCA 166 -4 (-2.35%)
  • TOBA 402 -26 (-6.07%)
  • TOTL 266 4 (1.53%)
  • TOWR 1,020 15 (1.49%)
  • TOYS 560 15 (2.75%)
  • TOYS-W 12 0 (0.00%)
  • TPIA 7,200 75 (1.05%)
  • TPMA 360 -4 (-1.10%)
  • TRIM 110 -1 (-0.90%) © 2010 IMQ - LKBN ANTARA
  • TRIN 224 2 (0.90%)
  • TRIN-W 9 0 (0.00%)
  • TRIS 198 -2 (-1.00%)
  • TRJA 150 -4 (-2.60%)
  • TRST 390 0 (0.00%)
  • TRUK 142 2 (1.43%)
  • TRUS 330 -8 (-2.37%)
  • TSPC 1,335 50 (3.89%)
  • TUGU 1,485 -110 (-6.90%)
  • TURI 1,350 45 (3.45%)
  • UANG 218 18 (9.00%)
  • UCID 1,470 10 (0.68%)
  • ULTJ 1,705 5 (0.29%)
  • UNIC 3,630 30 (0.83%)
  • UNIT 143 -7 (-4.67%)
  • UNSP 80 0 (0.00%)
  • UNTR 23,200 325 (1.42%)
  • UNVR 7,925 125 (1.60%)
  • VICO 85 -2 (-2.30%)
  • VINS 90 -2 (-2.17%)
  • VIVA 50 0 (0.00%)
  • VOKS 192 0 (0.00%)
  • WAPO 62 -4 (-6.06%)
  • WEGE 160 5 (3.23%)
  • WEHA 50 -1 (-1.96%) © 2010 IMQ - LKBN ANTARA
  • WICO 470 -35 (-6.93%)
  • WIIM 328 10 (3.14%)
  • WIKA 1,115 55 (5.19%)
  • WINS 96 1 (1.05%)
  • WOMF 226 10 (4.63%)
  • WOOD 368 -2 (-0.54%)
  • WOWS 54 2 (3.85%)
  • WSBP 142 4 (2.90%)
  • WSKT 505 15 (3.06%)
  • WTON 234 4 (1.74%)
  • XBNI 847 20 (2.42%)
  • XCID 75 0 (0.00%)
  • XIHD 380 5 (1.33%)
  • XIIC 870 6 (0.69%)
  • XIIF 425 13 (3.16%)
  • XIIT 433 11 (2.61%)
  • XIJI 533 4 (0.76%)
  • XISC 482 -6 (-1.23%)
  • XISR 311 3 (0.97%)
  • XMIG 131 -1 (-0.76%)
  • XPMI 750 0 (0.00%)
  • XSBC 85 -2 (-2.30%)
  • XSSI 89 0 (0.00%)
  • YELO 50 0 (0.00%)
  • YELO-W 5 0 (0.00%) © 2010 IMQ - LKBN ANTARA
  • YPAS 390 68 (21.12%)
  • YULE 200 0 (0.00%)
  • ZINC 129 1 (0.78%)
  • ZONE 374 -2 (-0.53%)
Aptorum Group announces further positive data for its ALS-4 small molecule Anti-virulence (Non-bactericidal) drug candidate for the treatment of infections caused by Staphylococcus aureus and on track targeted for IND submission in H2 2020
Published: 10 Feb 2020 20:35 WIB


IMQ, Jakarta —  NEW YORK--(Antara/BUSINESS WIRE)-- Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive data from its current investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or “S. aureus”), including methicillin-resistant Staphylococcus aureus (MRSA, one of the “super-bugs”), based on a novel anti-virulence non-bactericidal approach. Subject to completion of the current studies, Aptorum Group targets to submit IND for ALS-4 in second half of 2020 and commence a phase 1 trial in North America.

ALS-4 is a small molecule which inhibits dehydrosqualene desaturase of S. aureus (incl. MRSA), an enzyme that is critically involved in the biosynthesis of staphyloxanthin, a commonly visible “golden pigment” covering the bacteria. Staphyloxanthin is believed to be primarily responsible for the bacteria’s defense mechanism against the attack from reactive oxygen species (ROS) deployed by phagocytic cells and neutrophils.1

Through inhibiting the production of staphyloxanthin, we believe that ALS-4 renders S. aureus highly susceptible to the host’s immune defense (see below for in vivo data and experimental outline). This novel mechanism is significantly different from the bactericidal approach found in currently marketed antibiotics used to treat S. aureus, which are experiencing increasing drug resistance issues2. Specifically, MRSA infections in humans typically exhibit high rates of morbidity and mortality and can cause metastatic or complicated infections such as infective endocarditis or sepsis, with relapse and hospital readmission after S. aureus bacteremia common and costly3.

Based on our testing in a rat bacteremia survival model, a lethal (109 CFU) dose of MRSA (USA300-LAC) was introduced through the tail vein. ALS-4 was administered orally at 10mg/kg per animal 30 minutes after the infection for twice a day thereafter (N=9). A control untreated group was given a sterile vehicle solution (N=9). Survival was monitored for 7 days. 0 out of 9 animals (0%) in the control untreated group survived past day 4, in contrast, 5 out of 9 animals (56%) treated with ALS-4 survived past day 7, which is determined to be statistically significant compared with the control group (p=0.013).

In addition we conducted a study in a non-lethal rat bacteremia infection model. The animals were challenged with a non-lethal (107 CFU) dose of MRSA (USA300-LAC) through the tail vein. In order to simulate a more realistic clinical scenario, treatment was introduced 14-days after the model induction, where ALS-4 was administered orally twice a day at 10mg/kg per animal (N=8). A control untreated group was given a sterile vehicle solution (N=8). After 7 days of ALS-4 treatment, the kidneys were collected and the bacterial titers were measured. Remarkably, ALS-4 reduced the organ bacterial load by 99.5%, from 63,096±18 CFU/g in the control group to 316±49 CFU/g in the ALS-4 treated group, which is determined to be statistically significant (p=0.01).

Last but not least, ALS-4 has successfully inhibited staphyloxanthin production in 11 strains of S. aureus. These include 5 strains of Methicillin-sensitive S. aureus (MSSA): SH1000, HG003, USA300-JE2, Newman, and ATCC29213 with an IC50 of 70.5±6nM, 54.4±4nM, 37.7±4nM, 23.7±1nM, and 30.02±5nM respectively; 5 strains of Methicillin-resistant S. aureus (MRSA): USA300, USA300-3, USA300-LAC, ST239III, and COL, with an IC50 of 30.8±5nM, 42.8±6nM, 43.6±5nM, 16.3±8nM, and 0.9±1nM respectively; and 1 strain of vancomycin-intermediate S. aureus (VISA), Mu3 with an IC50 of 2.6±1nM.

Based on our testing, we believe ALS-4 increases the susceptibility of S. aureus including MRSA to oxidative damage by inhibiting production of staphyloxanthin,. In a hydrogen peroxide killing assay, after the addition of 1.5% H2O2, ALS-4 demonstrated an additional reduction of bacterial CFU by 93.5%, from 61,600±6437 CFU/ml in the untreated group to 4,000±230 CFU/ml in the ALS-4 treated group, which is determined to be statistically significant (p=0.003).

With respect to the study carried out to investigate the capability of ALS-4 to induce antibiotic resistance in S. aureus after prolonged exposure, USA300-LAC was cultured in 3 different conditions for 10 days. For the treatment group 1 µM of ALS-4 was added; for the positive control group 0.12 µg/mL of clindamycin and 16 µg/mL of erythromycin was added from day 1 to day 4, after which clindamycin was withdrawn. For the negative control group, dimethyl sulfoxide (DMSO) was added. On day 11, the bacteria were harvested and then cultured for 16 hr for the determination of the MIC of clindamycin. The prolonged exposure to ALS-4 or DMSO does not affect the MIC value of clindamycin (0.12 µg/mL); while the prolonged exposure to clindamycin + erythromycin triggers antibiotics resistance rapidly with the MIC increased from 0.12 µg/mL to greater than 5 µg/mL.

Based on our study we believe ALS-4 is unlikely to be prone to drug resistance since it is non-bactericidal. Growth inhibition studies were performed on different strains of S. aureus and other bacteria, including 3 strains of MSSA (ATCC29212, SH1000 and HG003), 1 strain of MRSA (USA300), 1 strain of VISA (ATCC700698 Mu3), as well as 6 different bacteria (E. coli, A. baumannii, S. cerevisiae, B. subtilis, E. faecalis, and K. pneumoniae). In all of the tested strains of bacteria, no growth inhibition effect was observed at the highest tested concentration of ALS-4 (250uM). Therefore ALS-4 does not appear to have any direct bacteriostatic or bactericidal activity against many species of bacteria, thus greatly reducing the selection pressure for drug resistance to emerge.

We also assessed the potential impact on the efficacy of vancomycin, the mainstay of treatment for infections caused by MRSA, when used in conjunction with ALS-4. 8 different strains of S. aureus (USA300 FPR3757, USA300-3, USA300-LAC, USA300-JE2, Mu3, HG003, ATCC29213 and clinical isolate ST239III) were used in this study. Our data showed that no effect on the MIC of vancomycin was observed when the concentration of ALS-4 was below 25 μM. Therefore, we believe that ALS-4 does not interfere with the action of vancomycin.

In addition, compared with the current mainstay of treatment for S. aureus infections such as vancomycin or daptomycin which is typically administered in an IV injectable form (with the exception of an oral form vancomycin specifically for treatment of Clostridium difficile diarrhea and staphylococcal enterocolitis only), an oral active agent enables wider market penetration targeting both outpatient as well as potential prophylactic markets.

GLP Toxicity Data

ALS-4 is currently undergoing IND-enabling studies and has so far shown positive safety profiles. As elucidated in our previous press release dated September 9, 2019, ALS-4 did not show any mutagenicity in the in vitro Ames tests. Our currently generated in vitro micronucleus test results also showed that ALS-4 is not genotoxic, indicating the non-mutagenic nature of the drug. Furthermore, the results of the in vitro hERG assay study predicts a low risk of ALS-4 causing cardiac QT prolongation.

For further general presentation, please visit: http://ir.aptorumgroup.com/static-files/bcf77574-7bd6-4b9d-8110-d53837238f16

For further technical presentation, please visit: http://ir.aptorumgroup.com/static-files/66346f79-7a03-474a-89be-0eaafaa00d9d

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases and other disease areas.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

1 mBio 2017 8(5): e01224-17
2 Microbiol Spectr. 2019 Mar;7(2)
3 Clin Infect Dis. 2019 Nov 27;69(12):2112-2118

Contacts

Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com

Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com

Source: Aptorum Group Limited
Author: Business Wire
-
POPULAR NEWS